PPI-targeted therapeutic - Cyclenium Pharma/SickKids
Latest Information Update: 04 Jul 2024
At a glance
- Originator Cyclenium Pharma
- Developer Cyclenium Pharma; SickKids
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-protein interaction modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 02 May 2024 Early research in Cancer in Canada (unspecified route), prior to May 2024 (Cyclenium Pharma pipeline, May 2024)